Cisplatin is one of the most effective cytotoxic agents in the treatment of solid malignancies, but its use is limited by several side effects. Among them, peripheral neurotoxicity can be dose limiting. A liposomal formulation of cisplatin, Lipoplatin™, was developed to reduce the systemic toxicity of cisplatin but without preventing its efficacy. The aim of this study was to use an animal model to establish, through a multimodal approach, whether chronic treatment with two different schedules of Lipoplatin™, selected within the range of its anticancer effective dose, is less neurotoxic than cisplatin administration.
Canta, A., Chiorazzi, A., Carozzi, V., Meregalli, C., Oggioni, N., Sala, B., et al. (2011). In vivo comparative study of the cytotoxicity of a liposomal formulation of cisplatin (lipoplatin™). CANCER CHEMOTHERAPY AND PHARMACOLOGY, 68(4), 1001-1008 [10.1007/s00280-011-1574-3].
In vivo comparative study of the cytotoxicity of a liposomal formulation of cisplatin (lipoplatin™)
CANTA, ANNALISA ROSANNA;CHIORAZZI, ALESSIA;CAROZZI, VALENTINA ALDA;MEREGALLI, CRISTINA;OGGIONI, NORBERTO;SALA, BARBARA;AVEZZA, FEDERICA;CAVALETTI, GUIDO ANGELO
2011
Abstract
Cisplatin is one of the most effective cytotoxic agents in the treatment of solid malignancies, but its use is limited by several side effects. Among them, peripheral neurotoxicity can be dose limiting. A liposomal formulation of cisplatin, Lipoplatin™, was developed to reduce the systemic toxicity of cisplatin but without preventing its efficacy. The aim of this study was to use an animal model to establish, through a multimodal approach, whether chronic treatment with two different schedules of Lipoplatin™, selected within the range of its anticancer effective dose, is less neurotoxic than cisplatin administration.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
